1. Home
  2. GROW vs SNTI Comparison

GROW vs SNTI Comparison

Compare GROW & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo U.S. Global Investors Inc.

GROW

U.S. Global Investors Inc.

N/A

Current Price

$3.13

Market Cap

32.7M

Sector

Finance

ML Signal

N/A

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

HOLD

Current Price

$0.45

Market Cap

31.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GROW
SNTI
Founded
1968
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.7M
31.5M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
GROW
SNTI
Price
$3.13
$0.45
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.50
AVG Volume (30 Days)
17.0K
228.0K
Earning Date
05-11-2026
05-06-2026
Dividend Yield
3.53%
N/A
EPS Growth
N/A
77.31
EPS
0.27
N/A
Revenue
$23,850,609.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$11.59
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.23
$0.33
52 Week High
$3.65
$2.88

Technical Indicators

Market Signals
Indicator
GROW
SNTI
Relative Strength Index (RSI) 64.91 42.55
Support Level $3.10 $0.33
Resistance Level $3.22 $1.18
Average True Range (ATR) 0.08 0.04
MACD 0.02 0.03
Stochastic Oscillator 96.41 81.88

Price Performance

Historical Comparison
GROW
SNTI

About GROW U.S. Global Investors Inc.

US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.

About SNTI Senti Biosciences Inc.

Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).

Share on Social Networks: